Testosterone Replacement Therapy (TRT) improves cardiovascular biomarkers by modulating molecular pathways such as VEGF upregulation and NF-κB suppression. Transdermal formulations may have hematological safety advantages but do not yet show superior cardiovascular outcomes over intramuscular options [La Vignera & Condorelli, 2026].
Testosterone Replacement Therapy (TRT) improves cardiovascular biomarkers by modulating molecular pathways such as VEGF upregulation and NF-κB suppression. Transdermal formulations may have hematological safety advantages but do not yet show superior cardiovascular outcomes over intramuscular options [La Vignera & Condorelli, 2026].
• TRT enhances vascular health markers, improving inflammatory and oxidative stress profiles [La Vignera & Condorelli, 2026]. • Transdermal testosterone formulations potentially offer better hematological safety compared to intramuscular injections [La Vignera & Condorelli, 2026]. • Hypogonadal men show reduced EPCs and elevated EMPs, all improved by TRT [La Vignera & Condorelli, 2026]. • The interplay between sleep disturbances and hypogonadism affects metabolic and hormonal balances, often complicating diagnosis [Andersen et al., 2026].
Testosterone is a critical hormone influencing numerous physiological functions, including reproduction, metabolism, and cardiovascular health. In hypogonadal men, testosterone deficiency can lead to endothelial dysfunction and increased cardiovascular risks. Understanding the therapeutic role of testosterone replacement therapy (TRT) in ameliorating these risks is vital [La Vignera & Condorelli, 2026].
Recent literature highlights that TRT can improve various cardiovascular biomarkers in hypogonadal men. Circulating markers such as endothelial progenitor cells (EPCs), endothelial microparticles (EMPs), platelet reactivity, and inflammatory markers like IL-6 and TNF-α show improvement upon TRT administration [La Vignera & Condorelli, 2026]. These changes are modulated by molecular pathways, including PI3K/Akt/eNOS signaling and NF-κB pathway suppression, contributing to better vascular health.
Various testosterone formulations exist, including transdermal and intramuscular options. Evidence suggests that transdermal testosterone may offer slight advantages in hematological safety, providing more stable testosterone levels and reducing risks related to blood clots compared to intramuscular formulations. However, definitive superiority in long-term cardiovascular outcomes has not been fully established [La Vignera & Condorelli, 2026].
The decline in testosterone in aging men is often accompanied by metabolic dysfunctions and sleep-related issues. The complex interactions between these factors can complicate the diagnosis and management of hypogonadism. Sleep disorders, including obstructive sleep apnea, contribute significantly to the endocrine and metabolic disorder spectrum observed in hypogonadal men [Andersen et al., 2026].
The path forward involves refining TRT protocols to maximize benefits and minimize risks. Questions remain regarding the optimal combination of formulation type, dose, and administration frequency. Long-term studies focused on cardiovascular outcomes are necessary to confirm the comparative benefits of transdermal versus intramuscular testosterone. Furthermore, investigating the role of TRT in synchronizing hormonal, metabolic, and sleep-related dimensions presents a compelling area for future research [La Vignera & Condorelli, 2026; Andersen et al., 2026].
This research briefing is based on the verified PubMed records linked in the References & Citations section below.
Ask PepBot any follow-up question about this topic. It knows every study, every protocol, every dosing detail.
Send this cited research summary to someone who is asking the same question.
Keep exploring
Mechanism, study context, and related research for Testosterone
Browse every ChatPEP research guide
See side-by-side research comparisons